Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 15/20 | 0.61 |
| ▸ | THRA | P10827 | 4/20 | 0.52 |
| ▸ | THRB | P10828 | 4/20 | 0.52 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | ASPH | Q12797 | 1/20 | 0.52 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.52 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.52 |
| ▸ | EGLN2 | Q96KS0 | 8/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5030237 | 0.87 | EGLN1 (0.82) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL523956 | 0.82 | EGLN1 (0.60) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL523955 | 0.82 | EGLN1 (0.60) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL4757091 | 0.81 | EGLN1 (0.60) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL523845 | 0.77 | EGLN1 (0.86) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL30274439 | 0.77 | EGLN1 (0.86) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL28536064 | 0.77 | EGLN1 (0.70) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL10224804 | 0.76 | EGLN1 (0.67) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL522364 | 0.76 | THRA (0.84) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL523724 | 0.76 | EGLN1 (1.00) | EGLN1THRATHRBBBOX1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919463-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2006138511-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2006-12-28 | — | — | WO | disclosed |